Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Tofacitinib is a promising treatment for severe alopecia areata, with many patients experiencing complete or partial hair regrowth.

Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.

Sorafenib can cause facial acne-like eruptions, which improve after reducing the dose or stopping the drug.

Baricitinib effectively treats severe alopecia for up to 104 weeks.

Proxalutamide significantly lowered hospital admissions for male COVID-19 patients compared to a placebo.

ALRN-6924 can protect hair follicles from chemotherapy damage by temporarily stopping cell division.

Tofacitinib can be effective in treating hair loss caused by alopecia areata.

Baricitinib improves quality of life and reduces anxiety and depression in severe alopecia areata patients with hair regrowth.

Finasteride may improve prostate cancer treatment outcomes.

Ruxolitinib helps regrow hair in alopecia areata by blocking inflammation, reducing stress, and controlling cell death.

BBR-SA nanomedicine is a safe and effective treatment for breast cancer.

Oral bicalutamide is safe and effective for female hair loss.

Baricitinib helped improve hair, eyebrow, and eyelash growth in alopecia areata patients.

Stopping afatinib improved a rare scalp condition in a patient.

Rash from EGFRI treatment can indicate both side effects and treatment effectiveness.

Ruxolitinib can help regrow hair in severe alopecia areata.

Oxyresveratrol promotes hair growth and may help treat hair loss.

5-alpha reductase inhibitors can cause sexual, neurologic, endocrine, and cardiovascular side effects, but these are rare and usually stop after ending treatment.

Deuruxolitinib significantly helps regrow scalp hair in adults with moderate to severe alopecia areata.

Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.

Abrocitinib may effectively treat stubborn alopecia universalis.

Analog 23 is a promising compound for prostate cancer treatment.

Topical calcitriol appears safe and may reduce hair loss during chemotherapy.

MK-0773 is a moderate inhibitor of the SRD5A2 enzyme.

Inhibiting retinoic acid activates WNT signaling, potentially aiding hair disorder and skin cancer treatments.

Erlotinib can cause acne-like skin issues, needing early treatment and possible dosage adjustments.